(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/234457 A1

(51) International Patent Classification:
A61K 31/40 (2006.01) *A61P 25/24* (2006.01)

(21) International Application Number:
PCT/IB2022/054085

(22) International Filing Date:
03 May 2022 (03.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

17/307,858	04 May 2021 (04.05.2021)	US
17/670,123	11 February 2022 (11.02.2022)	US
63/313,792	25 February 2022 (25.02.2022)	US

(71) Applicant: **JANSSEN PHARMACEUTICALS, INC.** [US/US]; 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US).

(72) Inventors: **SCHMIDT, Mark**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **POPOVA, Vanina**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **SAVITZ, Adam**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **MELKOTE, Rama**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **DREVETS, Wayne C.**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **GOPAL, Srihari**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **PEMBERTON, Darrel**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE). **LAGISHETTY, Chakradhar**; Janssen Research & Development, LLC, 920 US Route 202, PO Box 300, Raritan, New Jersey 08869 (US). **KEZIC, Iva**; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse (BE).

(74) Agent: **SHIRTZ, Joseph F.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION

(57) Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

WO 2022/234457 A1